Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression

Gut

Volumn 65, Issue 4, 2016, Pages 548-554

  Kastelein, F ^a   Van Olphen, S H ^a   Steyerberg, E W ^a   Spaander, M C W ^a   Bruno, M J ^a   Biermann, K ^b   Geldof, H ^b   Van Der Valk, H ^b   Ter Borg, P C J ^b   Giard, R W M ^b   Felt, R J F ^b   Meijer, G A ^b   Alderliesten, J ^b   Heinhuis, R ^b   Ter Borg, F ^b   Arends, J W ^b   Kolkman, J J ^b   Van Baarlen, J ^b   Tan, T G ^b   Den Hartog, B ^b   Van Tilburg, A J P ^b   Engels, L G J B ^b   Vos, W ^b   Peters, F T M ^b   Karrenbeld, A ^b   Schenk, B E ^b   Moll, F ^b   Loffeld, R ^b   Flens, M ^b   Van Roermund, H ^b   Lockefeer, F ^b   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; BARRETT ESOPHAGUS; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SURVEILLANCE; EARLY CANCER; EARLY DIAGNOSIS; ENDOSCOPIC MUCOSAL RESECTION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL STENT; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS DILATATION; ESOPHAGUS DYSPLASIA; ESOPHAGUS PERFORATION; ESOPHAGUS RESECTION; ESOPHAGUS STENOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; RECURRENT DISEASE; SURVIVAL RATE; SURVIVAL TIME; ADENOCARCINOMA; CLINICAL TRIAL; DISEASE COURSE; ESOPHAGUS TUMOR; HEALTH SURVEY; MIDDLE AGED; PATHOLOGY; PRECANCER; SURVIVAL ANALYSIS;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; DISEASE PROGRESSION; EARLY DIAGNOSIS; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POPULATION SURVEILLANCE; PRECANCEROUS CONDITIONS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84960936462     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308802     Document Type: Article

References (44)

1. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011;103:1049-57.
2. de Jonge PJ, van Blankenstein M, Looman CW, et al. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010;59:1030-6.
3. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365:1375-83.
4. Sikkema M, de Jonge PJ, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:235-44; quiz e32.
5. Hameeteman W, Tytgat GN, Houthoff HJ, et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96(5 Pt1):1249-56.
6. Kastelein F, Spaander MC, Biermann K, et al. Role of acid suppression in the development and progression of dysplasia in patients with Barrett's esophagus. Dig Dis 2011;29:499-506.
7. http://www.cijfersoverkanker.nl/.
8. Lund O, Kimose HH, Aagaard MT, et al. Risk stratification and long-term results after surgical treatment of carcinomas of the thoracic esophagus and cardia. A 25-year retrospective study. J Thorac Cardiovasc Surg 1990;99:200-9.
9. Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet 2013;381:400-12.
10. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014;63:7-42.
11. Wang KK, Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-97.
12. Menon D, Stafinski T, Wu H, et al. Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy. BMC Gastroenterol 2010;10:111.
13. Pech O, May A, Manner H, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014;146:652-660.e1.
14. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84.
15. Homs MY, van Oijen MG, Wijnhoven BP, et al. Changes in diagnostic and treatment strategies of oesophageal cancer in the period from 2001 to 2009: a survey in the Netherlands. Eur J Gastroenterol Hepatol 2012;24:126-33.
16. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825-31.
17. Wang JS, Canto MI. Predicting Neoplastic Progression in Barrett's Esophagus. Ann Gastroentol Hepatol 2010;1:1-10.
18. Corley DA, Mehtani K, Quesenberry C, et al. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology 2013;145:312-19.e1.
19. Aldulaimi DM, Cox M, Nwokolo CU, et al. Barrett's surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival. Eur J Gastroenterol Hepatol 2005;17:943-50.
20. Chang LC, Oelschlager BK, Quiroga E, et al. Long-term outcome of esophagectomy for high-grade dysplasia or cancer found during surveillance for Barrett's esophagus. J Gastrointest Surg 2006;10:341-6.
21. Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003;98:1931-9.
22. Cooper GS, Kou TD, Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol 2009;104:1356-62.
23. Corley DA, Levin TR, Habel LA, et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122:633-40.
24. Ferguson MK, Durkin A. Long-term survival after esophagectomy for Barrett's adenocarcinoma in endoscopically surveyed and nonsurveyed patients. J Gastrointest Surg 2002;6:29-35; discussion 6.
25. Fountoulakis A, Zafirellis KD, Dolan K, et al. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. Br J Surg 2004;91:997-1003.
26. Grant KS, DeMeester SR, Kreger V, et al. Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2013;146:31-7.
27. Hoff SJ, Sawyers JL, Blanke CD, et al. Prognosis of adenocarcinoma arising in Barrett's esophagus. Ann Thorac Surg 1998;65:176-80; discussion 80-1.
28. Incarbone R, Bonavina L, Saino G, et al. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc 2002;16:263-6.
29. Peters JH, Clark GW, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994;108:813-21; discussion 21-2.
30. Roberts KJ, Harper E, Alderson D, et al. Long-term survival and cost analysis of an annual Barrett's surveillance programme. Eur J Gastroenterol Hepatol 2010;22:399-403.
31. van Sandick JW, van Lanschot JJ, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43:216-22.
32. Bhat SK, McManus DT, Coleman HG, et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study. Gut 2015;64:20-5.
33. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012;61:970-6.
34. Sharma P, Falk GW, Weston AP, et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006;4:566-72.
35. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: The Prague C & M criteria. Gastroenterology 2006;131:1392-9.
36. Abela JE, Going JJ, Mackenzie JF, et al. Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy. Am J Gastroenterol 2008;103:850-5.
37. http://www.cbs.nl/.
38. Kastelein F, Spaander MC, Biermann K, et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011;141:2000-8; quiz e13-4.
39. http://seer.cancer.gov/.
40. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94: 2043-53.
41. Kastelein F, van Olphen S, Steyerberg EW, et al. Surveillance in patients with Barrett's oesophagus: a cost-effectiveness analysis. Gut 2015;64:864-71.
42. Kastelein F, Biermann K, Steyerberg EW, et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2013;62:1676-83.
43. Kastelein F, Spaander MC, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2013;11:382-8.
44. Inadomi JM. Surveillance in Barrett's esophagus: a failed premise. Keio J Med 2009;58:12-18.